Skip to Content
Last Updated: 04/25/2012

Image-Guided Drug Delivery (R01)

Program Announcement

(Expiration date: May 8, 2013)

Keyvan Farahani, Ph.D.

The NCI encourages innovative translational research in the development of quantitative in vivo imaging characterization of image-guided drug delivery (IGDD) in cancer, including characterizations of the target, delivery validation, and therapy response. This initiative will support research in development of integrated imaging-based platforms for multifunctional and multiplexed drug delivery systems in cancer. Validation studies in non-human primates or large animal models and first-in-human studies directed towards translation of IGDD technology into the clinic will be considered appropriate for this initiative.

About the
Associate Director

Paula M. Jacobs, Ph.D. Paula M. Jacobs, Ph.D., is Associate Director, Cancer Imaging Program in the Division of Cancer Treatment and Diagnosis at the National Cancer Institute. She came to work at the NCI after 30 years in the pharmaceutical and medical device industries where she was a key developer of ultrasmall superparamagnetic iron oxide drugs as magnetic resonance imaging agents and iron replacement therapeutics. More…

For More Details
About CIP